THE ADVOCACY GROUP for EMERGENT BIOSOLUTIONS
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 17, 2019 | $30,000 | Replaced |
| 4th Quarter - Termination | Mar 4, 2019 | $30,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Defense DEF
NDAA - provisions related to biological and chemical defense
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT J DOTCHIN | — |
Health Issues HCR
FDA regulatory issues Issues related to Priority Review Voucher programs Opioid and heroin addiction legislation, Naloxone access, coprescribing / opioid prescribing
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT J DOTCHIN | — |
Budget/Appropriations BUD
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government Re-authorization of the Pandemic and All-Hazards Preparedness Act Department of Defense appropriations for Medical Countermeasures
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT J DOTCHIN | — |
Homeland Security HOM
HR 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT J DOTCHIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.